AGL · agilon health, inc.

Current Thesis

The leg an investor is buying is a value-based-care operator whose margin repair is filed rather than projected. The Q2 2026 release (2026-08-05, 8-K Ex-99.1) put medical margin at $197M against negative $53M a year earlier, adjusted EBITDA at $70M against negative $83M, and GAAP net income at $18M against a $104M loss, on revenue of $1.49B (+7% YoY). Full-year 2026 guidance was raised at the same print to $5.775–$5.860B revenue, $465–$505M medical margin, $75–$95M adjusted EBITDA and 535,000–550,000 platform members. Margin per member went up while the member base was deliberately cut.

What has changed since the last update is the calendar, not the fundamentals. No company disclosure has landed since 2026-08-05, no analyst action since JP Morgan's 2026-08-24 target revision, and no Q3 earnings date has been announced as of 2026-09-06. The 2026-09-04 close of $88.50 sits 31.8% under the $129.84 52-week high with RSI(14) at 33.1 — the fade is dated after the beat and after the 2026-08-11 Citi upgrade. The three management appearances between 2026-09-09 and 2026-09-16 are the only dated forums before a Q3 print whose date does not yet exist.

Bullish and bearish views on agilon health, inc.

The model's bull view on agilon health, inc. (AGL), in brief: The swing is in an 8-K, not a slide deck. The bear view: The company itself guides the step-down. Both cases follow in full.

Bull Case

• The swing is in an 8-K, not a slide deck. Medical margin $197M vs -$53M; adjusted EBITDA $70M vs -$83M; net income $18M vs -$104M (Q2 2026 release, 2026-08-05).
• The beat was wide on both lines. Adjusted EPS $1.04 against roughly $0.08 consensus; revenue $1.49B against roughly $1.44B (Q2 2026 earnings coverage, 2026-08-05).
• Guidance moved up mid-year. FY26 medical margin $465–$505M and adjusted EBITDA $75–$95M, against a company that reported a $104M quarterly loss twelve months earlier.
• The shrink carries numbers. Medicare Advantage membership 437,000, down about 12% YoY; total platform membership 549,000, down about 10%; revenue still grew 7% (Q2 2026 release, 2026-08-05).
• The REACH book produced measurable savings in its final years. Disclosed 2026-07-10: eight REACH ACOs generated $229M in gross savings at a 13.6% gross savings rate for performance year 2024, including $54M returned to the Medicare Trust Fund. That is the operating evidence management will be asked to extend past the model's sunset.
• Bear capitulation is dated. Citigroup upgraded to Neutral from Sell on 2026-08-11 at a $115 target, stating the Sell thesis had played out; Wells Fargo carries Overweight at $146.

Bear Case

• The company itself guides the step-down. Q3 2026: revenue $1.445–$1.475B, medical margin $105–$115M, adjusted EBITDA negative $5M to positive $5M. The $197M quarter is not an H2 run-rate.
• Balance sheet is thin for a risk-bearing model. Cash and marketable securities of $257M at 2026-06-30 against roughly breakeven guided Q3 EBITDA.
• 2027 has a structural hole. CMS built ACO REACH for performance years 2023 through 2026 and accepts no new applications; agilon reported roughly 112,000 REACH members in Q2 2026 versus about 116,000 a year earlier. No replacement path has been disclosed.
• The sell-side raised marks without changing stances. JP Morgan lifted its target to $85 from $31 on 2026-08-24 and kept Underweight — a target that sits under the 2026-09-04 close of $88.50. Truist Hold $112, Barclays Equal-Weight $111, Evercore In-Line $125.
• Shorts rebuilt into the move. 22.79M shares short, about 7.50% of float, up 25.4% month-over-month, 2.2 days to cover (short-interest screens, 2026-08-31).
• Trailing GAAP is still deeply negative: operating income -$463.2M and net income -$391.3M on public screen data as of 2026-08-31, against FY26 adjusted EBITDA guided to $75–$95M.

Setup & Price Structure

The 2026-09-04 close of $88.50 is 31.8% under the $129.84 high, with RSI(14) at 33.1 and a three-month price change of -7.2%. The $80 area is the floor of the range the stock has held since the August drawdown; losing it on a weekly close converts a post-beat fade into a downtrend with no dated support underneath until the Q3 print.

Positioning observables, stated as observables: eight sell-side revisions landed between 2026-08-06 and 2026-08-24 and the shares are lower than when that sequence began; short interest rose 25.4% month-over-month into 2026-08-31 while the price was falling; the lowest published mark on the sheet (JP Morgan, $85, 2026-08-24) is now inside the market's own range rather than far below it; and no equity issuance has been disclosed since the Q2 8-K, which matters for a $257M cash position. No theme cluster currently carries this name, so there is no group bid to lean on — a re-rating has to be manufactured out of company-specific disclosure.

On where the story sits: the narrative is maturing — the inflection was established by the 2026-08-05 print, the last genuine stance change was Citigroup's 2026-08-11 upgrade, and everything since has been mark-to-market revision into a tape that keeps drifting lower. Nothing new has entered the story in four weeks.

Catalyst Calendar (next 30 days)

• 2026-09-09 — Wells Fargo 21st Annual Healthcare Conference fireside chat. First public management forum since the 2026-08-05 print.
• 2026-09-14 — Jefferies Healthcare Services and Technology Conference fireside chat, 4:00pm ET (time revised on 2026-08-27 from the originally announced 4:30pm).
• 2026-09-16 — Deutsche Bank 2026 Healthcare Summit. Closes the September window; past this date, no company-dated event remains on the calendar.
• ~2026-10-06 (est.) — date-setting release for Q3 2026 results. Prior pattern: the Q3 2025 date was announced 2025-10-06 and the Q2 2026 date on 2026-07-07. As of 2026-09-06 no Q3 2026 date exists.
• ~2026-10-29 (est.) — Q3 2026 results. Falls outside the 30-day window; it is the next binary and the first test of whether Q2's margin was repricing or risk-adjustment timing.

What Would Change Our Mind

The cleanest break is a September window that passes without a 2027 number. Three appearances in eight days, ending 2026-09-16, and then an empty calendar until a Q3 date that has not been set: if management leaves those forums without framing the post-ACO REACH member base, the story runs on a single quarter of filed data for roughly six more weeks. Structurally, a weekly close below $80 gives up the range the stock has held since the August drawdown and turns the slide from $129.84 into a trend rather than a retracement.

On the fundamental side, a Q3 report that cuts the FY26 $465–$505M medical-margin range, or medical margin printing at or under the $105M guided floor, would place the Q2 swing in the prior-period true-up column. Running the other way, a disclosed 2027 partnership or member pipeline covering the roughly 112,000 REACH lives, or a Q3 date-setting release accompanied by reaffirmed FY guidance, restores a dated proof point the tape can price.

Correlation Notes

No active theme cluster carries this name, so the read is single-name; group-move logic does not apply here. The observable linkages are to Medicare Advantage cost trend — large MA payers presenting at the same September conference calendar are the read-across channel, and any of them raising a medical loss ratio outlook in that window would land directly on a globally capitated model like this one. The second linkage is CMS policy: the ACO REACH sunset at 2026-12-31 and the eventual 2027 MA rate framework set the size of the addressable book independent of execution. The third is the value-based-care enablement peer set, where sentiment has historically moved as a block on payer-utilization headlines rather than on any single operator's filings. That grouping is an inference from how the sub-sector has traded around payer prints, not a measured beta.